Ninety Seconds

This week, we’re kicking off our “Ninety Seconds of What’s Next” video series, with a quick look at the two items I’ll be obsessed with this week: the pricing of COVID-19 therapeutics and presidential polling. — Brian

Recommended Value

Welcome to Recommended Value, the W2O hub for value, access, pricing and reimbursement intelligence.

It’s never been more critical to understand the value environment, and there is no better way to stay connected with what matters than our newsletters. Our weekly Value Report (subscribe here) offers a comprehensive review, each Friday, of the week that was.

Our Recommended Daily Value newsletter — available with a paid subscriptions (get your free trial here) — brings readers the day’s news, along with original analyses and commentary, providing the information needed to make decisions in real time.

The Latest

Today, W2O is launching Recommended Value, a hub for news and commentary about the way health care value, price, access and reimbursement. It extends the work we’ve been doing with our industry-leading newsletters for more than five years, allowing W2O to expand our analysis and curation and bring more visibility to these critical issues.

Read More

NEW: Biden and Trump representatives went deep on drug pricing in a Patients for Affordable Drugs NOW Town Hall. Here were our takeaways from the event.

Go Deeper

Each day, we summarize and analyze the day’s news in Recommended Daily Value.

Sign Up Here

Our 2020 Election Scorecard is updated with snapshots of how the health conversation is shaping the Senate race in four battleground states.

Go Deeper

Peter Kolchinsky, RA Capital’s founder and managing partner, joins to talk about why so many of the policy ideas floated around drug-pricing are wrongheaded. Industry is going to have to give “a pound of flesh,” Kolchinsky argued, and he’s explicit on the business practices biopharma must abandon to get a fair system that still rewards innovation.

Listen Here

We made some bold predictions about drug-pricing in 2020 back in January. The crystal ball might have been too cloudy: we didn’t see the pandemic coming.

Read On

The Impact of COVID-19 on Minority Communities in America is a Functioning Tragedy

Our Lauren Oubre spoke with Dr. Robert Fullilove, Associate Dean for Community and Minority Affairs, Professor of Clinical Sociomedical Sciences at Columbia University about racial disparities in the United States and abroad, comparing COVID-19 with HIV and explaining how pharmaceutical companies have a role in bridging gaps in care.

Read More

Our Five Drug-Pricing Predictions for 2020

As the old Danish proverb goes, it’s hard to make predictions, especially about the future. That doesn’t stop us from — once a year — taking a stab at it. The value and pricing conversation is moving fast, making it critically important to try to think about what’s coming next.

Read More

Highlights from Our Redeeming Value Podcast

Oct. 20, 2020: Peter Kolchinsky on Where Drug-Pricing Policy Solutions Go Wrong
Listen Here

Sept. 29, 2020: Jason Shafrin on Where — and Why — ICER Really Matters
Listen Here

Sept. 16, 2020: Jason Buxbaum, Medicines and Life Expectancy
Listen here

RDV Image of the Week

Last week, we shared a new Health Affairs study that highlighted the rise in spending on orphan drugs for privately insured children. Ten orphan drugs accounted for 52.9% of total pediatric orphan drug spending in 2018, according to the study.

Here’s a closer look at these drugs and their share of total pediatric orphan drug spending: